Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | VNN1 | O95497 | 13/20 | 0.58 |
| ▸ | ECE1 | P42892 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pantothenic Acid SCHEMBL1261506 | 1.00 | PTGS1 (0.58) | PTGS1KCNH2VNN1ECE1 | |
| Pantothenic Acid, Racemic SCHEMBL1835339 | 0.94 | PTGS1 (0.62) | PTGS1KCNH2VNN1ECE1 | |
| Pantothenic Acid SCHEMBL21547 | 0.92 | PTGS1 (0.67) | PTGS1KCNH2VNN1ECE1 | |
| Pantothenic Acid SCHEMBL7016631 | 0.92 | PTGS1 (0.67) | PTGS1KCNH2VNN1ECE1 | |
| Pantothenic Acid SCHEMBL29872649 | 0.92 | PTGS1 (0.67) | PTGS1KCNH2VNN1ECE1 | |
| Pantothenic Acid, Racemic SCHEMBL5437 | 0.92 | PTGS1 (0.67) | PTGS1KCNH2VNN1ECE1 | |
| Pantothenic Acid SCHEMBL14126322 | 0.92 | PTGS1 (0.67) | PTGS1KCNH2VNN1ECE1 | |
| Pantothenic Acid SCHEMBL5436 | 0.92 | PTGS1 (0.67) | PTGS1KCNH2VNN1ECE1 | |
| Pantothenic Acid, Racemic SCHEMBL21114380 | 0.92 | PTGS1 (0.67) | PTGS1KCNH2VNN1ECE1 | |
| Pantothenic Acid, Racemic SCHEMBL27836313 | 0.91 | PTGS1 (0.55) | PTGS1KCNH2VNN1ECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250152533-A1 | Novel Beta-Alanine Compositions and Methods of Use Thereof | LEGACY CORPORATE LENDING, LLC, AS ADMINISTRATIVE AGENT | 2025-05-15 | — | — | US | disclosed |
| CN-117264862-A | Genetically engineered bacterium for high yield of D-pantothenic acid, construction method and application thereof | 浙江工业大学 | 2023-12-22 | — | — | CN | disclosed |
| US-8043841-B2 | Nucleic acid molecules encoding alanine 2,3-aminomutases | NOVOZYMES A/S (DK) | 2011-10-25 | — | — | US | disclosed |
| US-20110045573-A1 | ALANINE 2, 3-AMINOMUTASE | NOVOZYMES A/S | 2011-02-24 | — | — | US | disclosed |
| US-7846707-B2 | Nucleic acid molecules encoding alanine 2,3-aminomutases | NOVOZYMES A/S (DK) | 2010-12-07 | — | — | US | disclosed |
| US-20100099167-A1 | ALANINE 2, 3-AMINOMUTASE | NOVOZYMES A/S | 2010-04-22 | — | — | US | disclosed |
| US-7655451-B2 | Alanine 2,3-aminomutase | NOVOZYMES A/S (DK) | 2010-02-02 | — | — | US | disclosed |
| EP-1575881-B1 | ALANINE 2,3- AMINOMUTASE | NOVOZYMES AS (DK) | 2009-05-27 | — | — | EP | disclosed |
| US-20080124785-A1 | ALANINE 2, 3-AMINOMUTASE | CARGILL, INCORPORATED | 2008-05-29 | — | — | US | disclosed |
| US-7309597-B2 | To convert alpha-alanine to beta-alanine, beta-alanine, pantothenic acid, 3-hydroxypropionic acid | CARGILL, INCORPORATED (US) | 2007-12-18 | — | — | US | disclosed |
| EP-1575881-A4 | ALANINE 2,3- AMINOMUTASE | CARGILL INC (US) | 2006-02-01 | — | — | EP | disclosed |
| CN-1714146-A | Alanine 2, 3-aminomutase | CARGILL INC (US) | 2005-12-28 | — | — | CN | disclosed |
| US-20050221466-A1 | Alanine 2,3,aminomutase | CARGILL, INCORPORATED | 2005-10-06 | — | — | US | disclosed |
| EP-1575881-A2 | ALANINE 2,3- AMINOMUTASE | Cargill, Incorporated (US) | 2005-09-21 | — | — | EP | disclosed |
| EP-1575881-A3 | ALANINE 2,3- AMINOMUTASE | Cargill, Incorporated (US) | 2005-08-04 | — | — | EP | disclosed |
| WO-2003062173-A2 | ALANINE 2,3- AMINOMUTASE | CARGILL, INCORPORATED (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080124785-A1 | ALANINE 2, 3-AMINOMUTASE | ALAD, AGXT, ABAT | PTGS1 1225/4885KCNH2 4572/4885VNN1 44/4885 |
| US-20100099167-A1 | ALANINE 2, 3-AMINOMUTASE | ALAD, AGXT, ABAT | PTGS1 1225/4885KCNH2 4572/4885VNN1 44/4885 |
| US-20110045573-A1 | ALANINE 2, 3-AMINOMUTASE | ALAD, AGXT, ABAT | PTGS1 1225/4885KCNH2 4572/4885VNN1 44/4885 |
| US-20250152533-A1 | Novel Beta-Alanine Compositions and Methods of Use Thereof | GYS1, PYGM, AADAT | PTGS1 3625/4885KCNH2 4573/4885VNN1 1001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.